Capmatinib Detailed Medication Guide and Precautions

1. Drug information

Common name: Capmatinib (Capmatinib)

Product name:Tabrecta

Alias: capmatinib, capatinib, terita

2. Main treatment areas

Capmatinib is designed to treat a specific type of metastatic non-small cell lung cancer (NSCLC) in adult patients whose tumors harbor mesenchymal epithelial transition (MET) exon 14 skipping mutations.

3. Medication guidance

1) Pre-medication evaluation: Patients should first undergo genetic testing to confirm the presence of MET exon 14 skipping mutations. If the detection of plasma samples is unclear, further testing of tumor tissue is recommended.

2) Recommended dosage: 400mg twice a day, each time. It can be taken orally and has nothing to do with diet. Tablets should be swallowed whole and avoid chewing or crushing. If you miss a dose or vomit, you should not take the next dose as originally planned.

3) Dose adjustment: If adverse reactions occur, the doctor may adjust the dose, first reducing it to 300 mg twice a day, and then reducing it to 200 mg twice a day. If 200 mg is still intolerable, the drug should be discontinued.

4. Possible adverse reactions

Common adverse reactions include edema, nausea, musculoskeletal pain, etc. Severe reactions may include difficulty breathing, pneumonia, and more. If adverse reactions occur, please seek medical treatment promptly.

5. Drug storage recommendations

Capmatinib tablets should be stored in the original packaging with desiccant at a temperature controlled between 20°C and 25°C, with fluctuations allowed between 15°C and 30°C. Pay attention to moisture-proof, tablets not used within 6 weeks after opening should be discarded.

6. Precautions for special users

Female patients: During treatment and within one week after stopping the drug, it is recommended to take contraceptive measures and avoid breastfeeding.

Male patients: If your partner may become pregnant, it is recommended to take contraceptive measures during treatment and within one week after stopping the drug.

7. Principle of drug action

Capmatinib inhibitsThe activity of MET kinase, especially targeting MET exon 14 skipping mutants, blocks the growth signals of cancer cells, thereby achieving the effect of treating lung cancer. It can effectively inhibit the proliferation of cancer cells driven by MET mutations at clinically achievable concentrations, showing significant anti-tumor activity.